It’s not top dollar, but it’s good enough for Guidant Corp.

After a day of tense speculation whether Johnson & Johnson would remake its bid to buy the Indianapolis medical devices maker, the two companies announced late Wednesday a new deal. J&J has agreed to pay $23.2 billion, or $68.06 per Guidant share, up from its previous offer of $63 per share. For each Guidant share, J&J is offering $37.25 in cash and 0.493 shares of common J&J stock. The new offer comes as Guidant was weighing an upstart, $72-a-share bid from Boston Scientific Corp. of Natick, Mass.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]